Sientra, Inc. (NASDAQ:SIEN) Given Average Recommendation of “Buy” by Analysts

Sientra, Inc. (NASDAQ:SIENGet Rating) has been given a consensus recommendation of “Buy” by the nine brokerages that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $8.21.

Several research firms recently weighed in on SIEN. Lake Street Capital began coverage on Sientra in a report on Thursday, April 14th. They set a “buy” rating and a $8.00 price objective on the stock. Colliers Securities reissued a “buy” rating on shares of Sientra in a report on Tuesday, March 22nd. Stifel Nicolaus cut their price objective on Sientra from $11.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, March 24th. Canaccord Genuity Group cut their price objective on Sientra from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, March 29th. Finally, StockNews.com downgraded Sientra from a “hold” rating to a “sell” rating in a report on Tuesday.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in Sientra by 2.0% in the first quarter. BlackRock Inc. now owns 3,768,538 shares of the medical instruments supplier’s stock valued at $8,366,000 after purchasing an additional 74,896 shares during the last quarter. Panagora Asset Management Inc. bought a new stake in Sientra during the 1st quarter valued at $182,000. Bank of Montreal Can raised its holdings in Sientra by 66.7% during the 1st quarter. Bank of Montreal Can now owns 66,589 shares of the medical instruments supplier’s stock valued at $151,000 after acquiring an additional 26,649 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Sientra during the 1st quarter valued at $68,000. Finally, Oppenheimer & Co. Inc. raised its holdings in Sientra by 65.2% during the 1st quarter. Oppenheimer & Co. Inc. now owns 203,809 shares of the medical instruments supplier’s stock valued at $452,000 after acquiring an additional 80,409 shares during the period. Institutional investors and hedge funds own 82.42% of the company’s stock.

Shares of SIEN stock opened at $1.29 on Friday. The stock’s fifty day moving average price is $1.97 and its two-hundred day moving average price is $3.13. The company has a market cap of $80.44 million, a PE ratio of -0.75 and a beta of 2.11. Sientra has a fifty-two week low of $1.22 and a fifty-two week high of $9.14. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.10 and a current ratio of 1.76.

Sientra (NASDAQ:SIENGet Rating) last issued its earnings results on Wednesday, March 23rd. The medical instruments supplier reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.08). The business had revenue of $22.65 million during the quarter, compared to analyst estimates of $22.50 million. Sientra had a negative net margin of 112.89% and a negative return on equity of 865.36%. During the same period in the prior year, the business posted ($0.38) EPS. On average, equities analysts predict that Sientra will post -0.88 EPS for the current fiscal year.

Sientra Company Profile (Get Rating)

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Featured Articles

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.